Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis

• As the first-ever U.S. Food and Drug Administration (FDA) approved over-the-counter (OTC) naloxone in 2023, Emergent is working to expand access with NARCAN Nasal Spray and build on its longstanding efforts with public interest entities across the country 
• Hundreds of thousands of NARCAN Nasal Spray cartons are available in over 32,000 retail locations in the U.S., and Emergent is working to increase reach into workplaces, businesses and other locations
• Approximately 22 million doses of NARCAN Nasal Spray were distributed in the U.S. and Canada in 2023, and Emergent is committed to meeting any increase in demand driven by the evolving and worsening epidemic
• The recently announced ‘White House Challenge to Save Lives from Overdose’ is a nationwide call-to-action that includes increasing access to life-saving opioid overdose reversal medications, a program with direct alignment to Emergent’s strategy and efforts since the launch of NARCAN Nasal Spray in 2016
• Naloxone, the active ingredient in NARCAN Nasal Spray, is a life-saving medication that can reverse an overdose from opioids, including heroin, fentanyl, and prescription opioid medications, when given in time
  

GAITHERSBURG, Md., March 28, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) remains committed to fighting the ongoing opioid crisis by broadening access to, and awareness of, NARCAN Nasal Spray to help save lives in opioid overdose emergencies. In 2022, the U.S. Centers for Disease Control and Prevention (CDC) reported over 107,000 overdose deaths – a number that has risen almost every year and which has continued to break annual records.¹ This includes a rise in synthetic opioid overdoses mainly driven by fentanyl.¹ There is an inherent risk of potential overdose, wherever opioids are present, which has tragically become the leading cause of accidental death in the U.S.² These statistics only further underscore the need for multi-sectoral action to address and prevent opioid overdose deaths.

One year after Emergent obtained the historic OTC U.S. FDA approval in March 2023 and seven months since retail launch in August 2023, the availability of NARCAN Nasal Spray in pharmacies, grocery stores and online retailers has helped more people gain access to this life-saving product. Emergent and other stakeholders in the fight must continue raising awareness about the availability of products like NARCAN Nasal Spray, reducing stigma and further improving access for all Americans. Since the OTC launch, NARCAN Nasal Spray can be purchased at more than 32,000 mass drug, grocery, online retailers and e-commerce sites. Emergent is working with retail partners to make it easy to find and access, however each retailer ultimately determines in-store product placement.